Zymeworks Common Stock Stock Investor Sentiment
| ZYME Stock | USD 12.21 0.04 0.33% |
About 64% of Zymeworks Common's investor base is looking to short. The analysis of the overall investor sentiment regarding Zymeworks Common Stock suggests that many traders are alarmed. The current market sentiment, together with Zymeworks Common's historical and current headlines, can help investors time the market. In addition, many technical investors use Zymeworks Common Stock stock news signals to limit their universe of possible portfolio assets.
Comfort Level 36
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Zymeworks Common's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Zymeworks Common Stock.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Zymeworks Historical Sentiment
Although Zymeworks Common's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Zymeworks, such as negative comments on social media and news outlets, may cause fear in the market and push Zymeworks Common's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Zymeworks.
Zymeworks |
Zymeworks Common Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Zymeworks Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Zymeworks Common that are available to investors today. That information is available publicly through Zymeworks media outlets and privately through word of mouth or via Zymeworks internal channels. However, regardless of the origin, that massive amount of Zymeworks data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zymeworks Common news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zymeworks Common relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zymeworks Common's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zymeworks Common alpha.
Zymeworks Common Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Ecor1 Capital, Llc of 298818 shares of Zymeworks Common at 13.5289 subject to Rule 16b-3 | 12/19/2024 |
2 | Acquisition by Ecor1 Capital, Llc of 704488 shares of Zymeworks Common at 14.0776 subject to Rule 16b-3 | 12/20/2024 |
3 | Acquisition by Ecor1 Capital, Llc of 251502 shares of Zymeworks Common at 14.2508 subject to Rule 16b-3 | 12/23/2024 |
4 | Acquisition by Ecor1 Capital, Llc of 11958 shares of Zymeworks Common at 14.1241 subject to Rule 16b-3 | 12/24/2024 |
5 | Acquisition by Ecor1 Capital, Llc of 16692 shares of Zymeworks Common at 14.3804 subject to Rule 16b-3 | 12/26/2024 |
6 | Acquisition by Ecor1 Capital, Llc of 101659 shares of Zymeworks Common at 14.4914 subject to Rule 16b-3 | 12/27/2024 |
7 | Acquisition by Ecor1 Capital, Llc of 58988 shares of Zymeworks Common at 14.4661 subject to Rule 16b-3 | 12/30/2024 |
8 | Acquisition by Ecor1 Capital, Llc of 146501 shares of Zymeworks Common at 14.5695 subject to Rule 16b-3 | 12/31/2024 |
9 | Acquisition by Ecor1 Capital, Llc of 157880 shares of Zymeworks Common at 14.7796 subject to Rule 16b-3 | 01/02/2025 |
10 | Disposition of 11110 shares by Smith Jeffrey T L of Zymeworks Common at 14.9241 subject to Rule 16b-3 | 01/06/2025 |
11 | Wall Street Analysts Believe Zymeworks Could Rally 41.36 percent Heres is How to Trade | 01/07/2025 |
12 | Acquisition by Kenneth Galbraith of 192000 shares of Zymeworks Common subject to Rule 16b-3 | 01/10/2025 |
13 | Acquisition by Ecor1 Capital, Llc of 74125 shares of Zymeworks Common at 13.3946 subject to Rule 16b-3 | 01/13/2025 |
14 | Acquisition by Ecor1 Capital, Llc of 029 shares of Zymeworks Common at 14.0068 subject to Rule 16b-3 | 01/15/2025 |
15 | Acquisition by Ecor1 Capital, Llc of 121681 shares of Zymeworks Common at 13.885 subject to Rule 16b-3 | 01/16/2025 |
16 | Insider Trading | 01/17/2025 |
17 | Acquisition by Ecor1 Capital, Llc of 5086521 shares of Zymeworks Common at 1.0E-4 subject to Rule 16b-3 | 02/13/2025 |
18 | Zymeworks Announces Achievement of 14 Million Milestone from GSK Collaboration | 02/26/2025 |
19 | Apellis Pharmaceuticals, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/28/2025 |
20 | Zymeworks Q4 2024 Earnings Preview | 03/04/2025 |
21 | Zymeworks Inc. Reports Q4 Loss, Misses Revenue Estimates | 03/05/2025 |
22 | Zymeworks Inc Q4 2024 Earnings Call Highlights Strategic Shifts and Financial Insights | 03/06/2025 |
23 | Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. Estimates | 03/10/2025 |
24 | Zymeworks Coverage Initiated by Analysts at Lifesci Capital | 03/11/2025 |
25 | Acquisition by Ecor1 Capital, Llc of 468356 shares of Zymeworks Common at 12.4846 subject to Rule 16b-3 | 03/13/2025 |
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |